Julia Braverman - Medical Center, Boston University

基本信息

浏览量：21

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 75 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Administering Selected Subscales of Patient-Reported Outcome Questionnaires to Reduce Patient Burden and Increase Relevance: a Position Statement on a Modular Approach

Daniel Serrano,David Cella,Don Husereau,Bellinda King-Kallimanis,Tito Mendoza,Tomas Salmonson,Arthur Stone,Alexandra Zaleta,Devender Dhanda,Andriy Moshyk, Fei Liu,Alan L. Shields,Fiona Taylor, Sasha Spite,James W. Shaw,Julia Braverman

Quality of Life Research（2024）

引用1浏览0WOS引用

A Review of Meaningful Change Thresholds for EORTC QLQ-C30 and FACT-G Within Oncology

Nathan A. Clarke,Julia Braverman, Gill Worthy,James W. Shaw,Bryan Bennett,Devender Dhanda,Kim Cocks

Value in Healthno. 4 (2024): 458-468

引用3浏览0WOS引用

An International Survey Assessing the Effects of the Duration of Attack-Free Period on Health-Related Quality of Life for Patients with Hereditary Angioedema

Robbin Itzler,William R. Lumry, John Sears,Julia Braverman, Yinglei Li, Caroline J. Brennan,Gary G. Koch

Orphanet Journal of Rare Diseases（2024）

引用0浏览0WOS引用

Lisocabtagene Maraleucel for Second-Line Relapsed or Refractory Large B-cell Lymphoma: Patient-Reported Outcomes from the PILOT Study

Leo I. Gordon, Fei,Julia Braverman,Daanish Hoda,Nilanjan Ghosh,Mehdi Hamadani,Gerhard C. Hildebrandt,Lily Peng,Shien Guo,Ling Shi,Alison Sehgal

Haematologica（2024）

引用1浏览0WOS引用

Estimating the Minimally Important Difference for the EQ-5D-5L and EORTC QLQ-C30 in Cancer

Siobhan Bourke,Bryan Bennett,Yemi Oluboyede, Tara Li,Louise Longworth, Sian Bissell O’Sullivan,Julia Braverman,Ioana-Alexandra Soare,James W. Shaw

Health and quality of life outcomes（2024）

引用0浏览0WOS引用

Analysis of Patient-Reported Experiences Up to 2 Years after Receiving Idecabtagene Vicleucel (Ide-Cel, Bb2121) for Relapsed or Refractory Multiple Myeloma: Longitudinal Findings from the Phase 2 KarMMa Trial

Michel Delforge,Paula Rodriguez Otero,Nina Shah,Olga Moshkovich,Julia Braverman,Devender S. Dhanda,Sally Lanar,Jennifer Devlen,Matthew Miera,Heather Gerould,Timothy B. Campbell,Nikhil C. Munshi

Leukemia Research (2023): 107074-107074

引用7浏览0WOS引用

P-310 Treatment Preferences among Triple-Class Exposed Patients with Relapsed/refractory Multiple Myeloma in the United States (US), United Kingdom (UK), and Germany (DE): a Discrete Choice Experiment

Paula Rodriguez-Otero,Christine Michaels-Igbokwe,Hannah Collacott,Julia Braverman,Thomas Marshall,Antoine Tinel,Devender Dhanda

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）

引用0浏览0引用

An Indirect Treatment Comparison of Efficacy and Health-Related Quality of Life Following Treatment with Idecabtagene Vicleucel Versus Belantamab Mafodotin in Triple-Class Exposed Relapsed/refractory Patients with Multiple Myeloma

Paula Rodriguez Otero,Kevin Towle,Shannon Cope,Clyde Caisip,Faith E. Davies,Michel Delforge,Katja Weisel,Thomas S. Marshall,Korinna Karampampa,Dieter Ayers,Ali Mojebi,Julia Braverman,James Farrell,Devender Dhanda

LEUKEMIA & LYMPHOMA（2023）

引用0浏览0WOS引用

Linguistic Evaluation of Prefrontal Synthesis

Andrey Vyshedskiy,Katarina Radi, Megan Catherine DuBois, Emma Mugford,Victoria Maslova,Julia Braverman,Irene Piryatinsky

PsycTESTS Dataset (2022)

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn